Format

Send to

Choose Destination
J Med Virol. 2016 Dec;88(12):2044-2051. doi: 10.1002/jmv.24678. Epub 2016 Sep 20.

Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials.

Author information

1
Faculty of Science, Biophysics Department, Cairo University, Giza, Egypt. abdo@sci.cu.edu.eg, aelfiky@ictp.it.

Abstract

In the last few months, a new Zika virus (ZIKV) outbreak evolved in America. In accordance, World Health Organization (WHO) in February 2016 declared it as Public Health Emergency of International Concern (PHEIC). ZIKV infection was reported in more than 60 countries and the disease was spreading since 2007 but with little momentum. Many antiviral drugs are available in market or in laboratories under clinical trials, could affect ZIKV infection. In silico docking study were performed on the ZIKV polymerase to test some of Hepatitis C Virus (HCV) drugs (approved and in clinical trials). The results show potency of almost all of the studied compounds on ZIKV polymerase and hence inhibiting the propagation of the disease. In addition, the study suggested two nucleotide inhibitors (IDX-184 and MK0608) that may be tested as drugs against ZIKV infection. J. Med. Virol. 88:2044-2051, 2016.

KEYWORDS:

IDX-184; Zika virus; molecular modeling; nucleotide inhibitors; polymerase; protein-ligand docking

PMID:
27604059
DOI:
10.1002/jmv.24678
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center